The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab ; volume:84 ; number:12 ; day:13 ; month:11 ; year:2024 ; pages:1579-1601 ; date:12.2024
Drugs ; 84, Heft 12 (13.11.2024), 1579-1601, 12.2024
- Urheber
-
Kester, Robert
Zalani, Sunita
Ebbinghaus, Scot
Rubin, Eric
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-024-02111-7
- URN
-
urn:nbn:de:101:1-2503012104066.445273652790
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kester, Robert
- Zalani, Sunita
- Ebbinghaus, Scot
- Rubin, Eric
- SpringerLink (Online service)
Ähnliche Objekte (12)
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Evaluation of dosing strategy for pembrolizumab for oncology indications
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
Pembrolizumab
Approval voting
Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
On approval (DT)
Sparsentan: First Approval
Eplontersen: First Approval
Pexidartinib: First Approval
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Evaluation of dosing strategy for pembrolizumab for oncology indications
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
Pembrolizumab
Approval voting
Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
On approval (DT)
Sparsentan: First Approval
Eplontersen: First Approval
Pexidartinib: First Approval
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Evaluation of dosing strategy for pembrolizumab for oncology indications
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Accelerated Approval for Cancer Drugs in the United States and the Clinical Evidence Required for Conversion to Regular Approval
Pembrolizumab
Approval voting
Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
On approval (DT)
Sparsentan: First Approval
Eplontersen: First Approval